{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:11Z","timestamp":1786998371432,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ygyno.2021.01.022","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T18:37:19Z","timestamp":1612463839000},"page":"104-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study"],"prefix":"10.1016","volume":"161","author":[{"given":"Robert L.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpa","family":"Nick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Palancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan M.","family":"Fellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prahlad","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Schmeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Bodurka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa A.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.01.022_bb0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus, pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0015","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1006\/geno.1996.4569","article-title":"ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers","volume":"40","author":"Sulman","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.ygyno.2021.01.022_bb0025","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.4161\/cbt.10.12.13582","article-title":"Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer","volume":"10","author":"Merritt","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0030","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1158\/1078-0432.CCR-10-0017","article-title":"EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma","volume":"16","author":"Lee","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0035","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/cncr.24335","article-title":"EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer","volume":"115","author":"Kamat","year":"2009","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0040","first-page":"2301","article-title":"EphA2 overexpression causes tumorigenesis of mammary epithelial cells","volume":"61","author":"Zelinski","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0045","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0002-9440(10)63899-0","article-title":"Differential regulation of EphA2 in normal and malignant cells","volume":"162","author":"Walker-Daniels","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0050","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","article-title":"Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery","volume":"65","author":"Landen","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0055","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1517\/14728222.9.6.1179","article-title":"EphA2 as a target for ovarian cancer therapy","volume":"9","author":"Landen","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ygyno.2021.01.022_bb0060","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/jnci\/djj414","article-title":"Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer","volume":"98","author":"Landen","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0065","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4161\/cbt.5.12.3468","article-title":"Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer","volume":"5","author":"Landen","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0070","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/jnci\/djp231","article-title":"EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma","volume":"101","author":"Lee","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cmdc.201700217","article-title":"Chemoproteomics-aided medicinal chemistry for the discovery of EPHA2 inhibitors","volume":"12","author":"Heinzlmeir","year":"2017","journal-title":"ChemMedChem."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0080","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/sj.bjc.6604676","article-title":"Effects of dasatinib on EphA2 receptor yrosine kinase activity and downstream signalling in pancreatic cancer","volume":"99","author":"Chang","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.01.022_bb0085","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-12-0507","article-title":"A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer","volume":"18","author":"Secord","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0090","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-11-0215","article-title":"A novel platform for detection of CK+ and CK- CTCs","volume":"1","author":"Pecot","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12014-010-9055-y","article-title":"A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers","volume":"6","author":"Hennessy","year":"2010","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.ygyno.2021.01.022_bb0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2017.01.005","article-title":"Characterization of human cancer cell lines by reverse-phase protein arrays","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2021.01.022_bb0105","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","article-title":"Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells","volume":"5","author":"Tibes","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0110","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/1471-2164-13-282","article-title":"NetWalker: a contextual network analysis tool for functional genomics","volume":"13","author":"Komurov","year":"2012","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ygyno.2021.01.022_bb0115","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-13-2141","article-title":"Cross-talk between EphA2 and BRaf\/CRaf is a key determinant of response to Dasatinib","volume":"20","author":"Huang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.01.022_bb0120","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/bjc.2016.235","article-title":"L1CAM expression in endometrial carcinomas: an ENITEC collaboration study","volume":"115","author":"van der Putten","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.01.022_bb0125","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.19.00037","article-title":"Uterine Cancer: adjuvant therapy and Management of Metastatic Disease","volume":"37","author":"Creutzberg","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:56Z","timestamp":1758772736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0090825821000822"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}